The 10-second takeaway
For the quarter ended Dec. 31 (Q4), IDEXX Laboratories beat slightly on revenue and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased, and GAAP earnings per share improved.
Gross margins increased, operating margins increased, and net margins shrank.
IDEXX Laboratories booked revenue of $307.2 million. The nine analysts polled by S&P Capital IQ expected net sales of $303.9 million. Sales were 8.3% higher than the prior-year quarter's $283.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.67. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.63 per share on the same basis. GAAP EPS of $0.66 for Q4 were 9.7% higher than the prior-year quarter's $0.61 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 51.7%, 70 basis points better than the prior-year quarter. Operating margin was 18.0%, 10 basis points better than the prior-year quarter. Net margin was 12.4%, 40 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $314.5 million. On the bottom line, the average EPS estimate is $0.70.
Next year's average estimate for revenue is $1.30 billion. The average EPS estimate is $3.08.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 216 members out of 228 rating the stock outperform, and 12 members rating it underperform. Among 69 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 67 give IDEXX Laboratories a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IDEXX Laboratories is outperform, with an average price target of $82.14.
The healthcare investing landscape is littered with also-rans and a few major winners. Is IDEXX Laboratories the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add IDEXX Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.